- Report
- August 2025
- 184 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- September 2025
- 376 Pages
Global
From €5162EUR$5,850USD£4,465GBP
- Report
- March 2025
- 145 Pages
Global
From €2646EUR$2,999USD£2,289GBP
- Report
- December 2024
- 144 Pages
Global
From €2788EUR$3,160USD£2,412GBP
€3485EUR$3,950USD£3,014GBP
- Report
- September 2024
- 117 Pages
Global
From €3971EUR$4,500USD£3,434GBP
- Report
- December 2024
- 100 Pages
Global
From €5250EUR$5,950USD£4,541GBP
- Report
- April 2025
- 100 Pages
Global
From €5250EUR$5,950USD£4,541GBP
- Report
- May 2025
- 200 Pages
Global
From €2197EUR$2,490USD£1,900GBP
- Report
- August 2025
- 186 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 182 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 184 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 181 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- April 2025
- 175 Pages
Global
From €3962EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3962EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3962EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3962EUR$4,490USD£3,427GBP
- Report
- July 2025
- 175 Pages
Global
From €3962EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3962EUR$4,490USD£3,427GBP
- Report
- March 2025
- 175 Pages
Global
From €3962EUR$4,490USD£3,427GBP
- Report
- January 2025
- 175 Pages
Global
From €3962EUR$4,490USD£3,427GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more